Trials / Completed
CompletedNCT00549055
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration (AMD) In Real Life (Macureli Study).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Macugen | Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year) |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2007-10-25
- Last updated
- 2018-12-06
- Results posted
- 2010-10-27
Locations
4 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00549055. Inclusion in this directory is not an endorsement.